StretchDollar’s $6 million raise was led by Fika Ventures and Oscar Health and included participation from Precursor Ventures and Springbank. The post ICHRA Startup Secures $6M to Streamline Health Benefits for Small Businesses appeared first on MedCity News.
Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguci said. The post Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More…
NEW RICHLAND, Minn. — Floodwater seeped through the nursing home’s front door just before sunrise. Inside the New Richland Care Center, staff members rushed to move 36 residents out of the building on Sept. 19 while they still could. They pushed elderly residents in wheelchairs through 4-inch-deep water to buses waiting in the parking lot,…
Sanford Health is embedding AI into its EHR to turn vast patient data into actionable insights. Tools like a chronic kidney disease module and a personalized colon cancer screening model are helping clinicians catch disease earlier and tailor care to individual patients, explained Jeremy Cauwels, the health system’s chief medical officer. The post How Sanford…
In mid-2024 Blue Shield began its journey to create a comprehensive prior authorization platform solution
Top challenges impacting specialty pharmacy outcomes, and how health systems may achieve efficiencies and enhance performance for optimal outcomes. The post An Integrated Approach to Optimizing Specialty Pharmacy and Accelerating Performance appeared first on MedCity News.
Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over the Amgen drug that is currently the only approved treatment. The post After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset appeared first on MedCity…
Some of the company’s Pennsylvania treatment centers will need to backfill some beds because Empire State leaders are no longer allowing some residents to get care out of state. “At times, there are decisions made that we don’t, frankly, understand from an economic standpoint,” CFO Todd Young told an industry gathering.
Rocket Pharmaceuticals voluntarily withdrew its FDA submission for its Fanconi anemia gene therapy. The move follows a corporate restructuring over the summer that refocused the company on its cardiovascular programs. The post Rocket Pharmaceuticals Pulls FDA Filing for Rare Blood Disorder Gene Therapy appeared first on MedCity News.
By DAVID SHAYWITZ “There are decades where nothing happens; and there are weeks where decades happen,” said Lenin, probably never. It’s also a remarkably apt characterization of the last year in generative AI (genAI) — the last week in particular — which has seen the AI landscape shift so dramatically that even skeptics are now updating…